vs
渤健（BIIB）与罗布乐思（RBLX）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是罗布乐思的1.8倍（$2.5B vs $1.4B），渤健净利率更高（12.9% vs -22.3%，领先35.2%），罗布乐思同比增速更快（43.2% vs 2.0%），渤健自由现金流更多（$594.3M vs $308.6M），过去两年罗布乐思的营收复合增速更高（32.9% vs 0.3%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
罗布乐思（Roblox Corporation）是总部位于美国加利福尼亚州圣马特奥的游戏企业，由大卫·巴斯祖奇与埃里克·卡塞尔于2004年共同创立。公司核心产品为同名线上游戏创作平台Roblox，于2006年正式上线，截至2024年12月底全球员工规模已超2400人。
BIIB vs RBLX — 直观对比
营收规模更大
BIIB
是对方的1.8倍
$1.4B
营收增速更快
RBLX
高出41.2%
2.0%
净利率更高
BIIB
高出35.2%
-22.3%
自由现金流更多
BIIB
多$285.7M
$308.6M
两年增速更快
RBLX
近两年复合增速
0.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.5B | $1.4B |
| 净利润 | $319.5M | $-316.0M |
| 毛利率 | — | 77.7% |
| 营业利润率 | — | -25.3% |
| 净利率 | 12.9% | -22.3% |
| 营收同比 | 2.0% | 43.2% |
| 净利润同比 | 32.8% | -43.9% |
| 每股收益（稀释后） | $2.15 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBRBLX
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.3B | $1.4B | ||
| Q3 25 | $2.5B | $1.4B | ||
| Q2 25 | $2.6B | $1.1B | ||
| Q1 25 | $2.4B | $1.0B | ||
| Q4 24 | $2.5B | $988.2M | ||
| Q3 24 | $2.5B | $919.0M | ||
| Q2 24 | $2.5B | $893.5M |
净利润BIIBRBLX
| Q1 26 | $319.5M | — | ||
| Q4 25 | $-48.9M | $-316.0M | ||
| Q3 25 | $466.5M | $-255.6M | ||
| Q2 25 | $634.8M | $-278.4M | ||
| Q1 25 | $240.5M | $-215.1M | ||
| Q4 24 | $266.7M | $-219.6M | ||
| Q3 24 | $388.5M | $-239.3M | ||
| Q2 24 | $583.6M | $-205.9M |
毛利率BIIBRBLX
| Q1 26 | — | — | ||
| Q4 25 | 78.3% | 77.7% | ||
| Q3 25 | 73.4% | 78.2% | ||
| Q2 25 | 77.1% | 78.2% | ||
| Q1 25 | 74.1% | 78.3% | ||
| Q4 24 | 76.2% | 77.9% | ||
| Q3 24 | 74.1% | 77.7% | ||
| Q2 24 | 77.8% | 77.8% |
营业利润率BIIBRBLX
| Q1 26 | — | — | ||
| Q4 25 | -2.5% | -25.3% | ||
| Q3 25 | 22.0% | -21.8% | ||
| Q2 25 | 28.1% | -29.8% | ||
| Q1 25 | 12.8% | -24.6% | ||
| Q4 24 | 11.9% | -24.7% | ||
| Q3 24 | 18.3% | -30.4% | ||
| Q2 24 | 28.3% | -26.6% |
净利率BIIBRBLX
| Q1 26 | 12.9% | — | ||
| Q4 25 | -2.1% | -22.3% | ||
| Q3 25 | 18.4% | -18.8% | ||
| Q2 25 | 24.0% | -25.8% | ||
| Q1 25 | 9.9% | -20.8% | ||
| Q4 24 | 10.9% | -22.2% | ||
| Q3 24 | 15.8% | -26.0% | ||
| Q2 24 | 23.7% | -23.0% |
每股收益（稀释后）BIIBRBLX
| Q1 26 | $2.15 | — | ||
| Q4 25 | $-0.35 | $-0.44 | ||
| Q3 25 | $3.17 | $-0.37 | ||
| Q2 25 | $4.33 | $-0.41 | ||
| Q1 25 | $1.64 | $-0.32 | ||
| Q4 24 | $1.82 | $-0.32 | ||
| Q3 24 | $2.66 | $-0.37 | ||
| Q2 24 | $4.00 | $-0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.4B | $3.1B |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $18.7B | $394.5M |
| 总资产 | $29.5B | $9.6B |
| 负债/权益比越低杠杆越低 | — | 2.98× |
8季度趋势，按日历期对齐
现金及短期投资BIIBRBLX
| Q1 26 | $3.4B | — | ||
| Q4 25 | — | $3.1B | ||
| Q3 25 | — | $2.9B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.7B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.4B |
总债务BIIBRBLX
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | $1.2B | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | $1.2B | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — |
股东权益BIIBRBLX
| Q1 26 | $18.7B | — | ||
| Q4 25 | $18.3B | $394.5M | ||
| Q3 25 | $18.2B | $407.6M | ||
| Q2 25 | $17.6B | $353.2M | ||
| Q1 25 | $17.0B | $310.7M | ||
| Q4 24 | $16.7B | $221.4M | ||
| Q3 24 | $16.4B | $189.9M | ||
| Q2 24 | $15.9B | $121.5M |
总资产BIIBRBLX
| Q1 26 | $29.5B | — | ||
| Q4 25 | $29.4B | $9.6B | ||
| Q3 25 | $29.2B | $8.6B | ||
| Q2 25 | $28.3B | $7.8B | ||
| Q1 25 | $28.0B | $7.5B | ||
| Q4 24 | $28.0B | $7.2B | ||
| Q3 24 | $28.3B | $6.7B | ||
| Q2 24 | $26.8B | $6.5B |
负债/权益比BIIBRBLX
| Q1 26 | — | — | ||
| Q4 25 | 0.34× | 2.98× | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | 5.48× | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $607.0M |
| 自由现金流经营现金流 - 资本支出 | $594.3M | $308.6M |
| 自由现金流率自由现金流/营收 | 24.0% | 21.8% |
| 资本支出强度资本支出/营收 | — | 21.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.4B | $1.4B |
8季度趋势，按日历期对齐
经营现金流BIIBRBLX
| Q1 26 | — | — | ||
| Q4 25 | $511.9M | $607.0M | ||
| Q3 25 | $1.3B | $546.2M | ||
| Q2 25 | $160.9M | $199.3M | ||
| Q1 25 | $259.3M | $443.9M | ||
| Q4 24 | $760.9M | $184.5M | ||
| Q3 24 | $935.6M | $247.4M | ||
| Q2 24 | $625.8M | $151.4M |
自由现金流BIIBRBLX
| Q1 26 | $594.3M | — | ||
| Q4 25 | $468.0M | $308.6M | ||
| Q3 25 | $1.2B | $443.6M | ||
| Q2 25 | $134.3M | $176.7M | ||
| Q1 25 | $222.2M | $426.5M | ||
| Q4 24 | $721.6M | $120.6M | ||
| Q3 24 | $900.6M | $218.0M | ||
| Q2 24 | $592.3M | $111.7M |
自由现金流率BIIBRBLX
| Q1 26 | 24.0% | — | ||
| Q4 25 | 20.5% | 21.8% | ||
| Q3 25 | 48.4% | 32.6% | ||
| Q2 25 | 5.1% | 16.3% | ||
| Q1 25 | 9.1% | 41.2% | ||
| Q4 24 | 29.4% | 12.2% | ||
| Q3 24 | 36.5% | 23.7% | ||
| Q2 24 | 24.0% | 12.5% |
资本支出强度BIIBRBLX
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 21.1% | ||
| Q3 25 | 1.8% | 7.5% | ||
| Q2 25 | 1.0% | 2.1% | ||
| Q1 25 | 1.5% | 1.7% | ||
| Q4 24 | 1.6% | 6.5% | ||
| Q3 24 | 1.4% | 3.2% | ||
| Q2 24 | 1.4% | 4.4% |
现金转化率BIIBRBLX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.73× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | — | ||
| Q2 24 | 1.07× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Product revenue, net | $1.8B | 71% |
| Royalty revenue on sales of OCREVUS | $317.2M | 13% |
| Contract manufacturing, royalty and other revenue | $246.9M | 10% |
| Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO | $94.7M | 4% |
| Alzheimer's collaboration Revenue | $59.5M | 2% |
| Other revenue from anti-CD20 therapeutic programs | $7.2M | 0% |
RBLX
暂无分部数据
